Stalevo: Clinical Trials

3 trials of Stalevo, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed. 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 33Completed 3

Follow Stalevo: new trials by email Literature Review of Stalevo trials Research Report on Stalevo

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
IPX066, CLE - Parkinson's Disease
Phase 3CompletedImpax Laboratories, LLC1102010-05-012019-10-29
A Study to Evaluate Fixed Dose Carbidopa/Levodopa/Entacapone Versus Immediate Release Carbidopa/Levodopa
capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg) - Parkinson's Disease
Phase 3CompletedNovartis4932005-08-012017-05-17
Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy
Carbidopa/levodopa/entacapone, Immediate release carbidopa/levodopa - Parkinson's Disease
Phase 3CompletedNovartis Pharmaceuticals7472004-09-012012-04-23

Conditions studied

Parkinson Disease (3)  ·  Dyskinesias (2)

Sponsors

Impax Laboratories, LLC (1)  ·  Novartis (1)  ·  Novartis Pharmaceuticals (1)

Countries

Italy (3)  ·  United States (3)  ·  Canada (2)  ·  France (2)  ·  Germany (2)  ·  Turkey (Türkiye) (2)  ·  Austria (1)  ·  Belgium (1)  ·  Czechia (1)  ·  Finland (1)  ·  Greece (1)  ·  Israel (1)  ·  Poland (1)  ·  Portugal (1)  ·  Spain (1)

Results publications

PMID 19058133, PMID 20582993, PMID 30425824